ICU MEDICAL INC (ICUI) Stock Price & Overview

NASDAQ:ICUI • US44930G1076

Current stock price

129.4 USD
-0.53 (-0.41%)
At close:
129.4 USD
0 (0%)
After Hours:

The current stock price of ICUI is 129.4 USD. Today ICUI is down by -0.41%. In the past month the price decreased by -14.28%. In the past year, price decreased by -7.3%.

ICUI Key Statistics

52-Week Range107 - 160.29
Current ICUI stock price positioned within its 52-week range.
1-Month Range123.53 - 158.05
Current ICUI stock price positioned within its 1-month range.
Market Cap
3.195B
P/E
16.68
Fwd P/E
15.64
EPS (TTM)
7.76
Dividend Yield
N/A

ICUI Stock Performance

Today
-0.41%
1 Week
+2.34%
1 Month
-14.28%
3 Months
-12.13%
Longer-term
6 Months +9.36%
1 Year -7.30%
2 Years +21.07%
3 Years -21.24%
5 Years -36.76%
10 Years +24.81%

ICUI Stock Chart

ICU MEDICAL INC / ICUI Daily stock chart

ICUI Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to ICUI. When comparing the yearly performance of all stocks, ICUI is a bad performer in the overall market: 76.57% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ICUI Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ICUI. ICUI has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ICUI Earnings

On February 19, 2026 ICUI reported an EPS of 1.91 and a revenue of 535.94M. The company beat EPS expectations (10.68% surprise) and missed revenue expectations (-0.98% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported$1.91
Revenue Reported535.94M
EPS Surprise 10.68%
Revenue Surprise -0.98%

ICUI Forecast & Estimates

12 analysts have analysed ICUI and the average price target is 187.27 USD. This implies a price increase of 44.72% is expected in the next year compared to the current price of 129.4.

For the next year, analysts expect an EPS growth of 6.62% and a revenue growth -1.33% for ICUI


Analysts
Analysts83.33
Price Target187.27 (44.72%)
EPS Next Y6.62%
Revenue Next Year-1.33%

ICUI Groups

Sector & Classification

ICUI Financial Highlights

Over the last trailing twelve months ICUI reported a non-GAAP Earnings per Share(EPS) of 7.76. The EPS increased by 24.76% compared to the year before.


Income Statements
Revenue(TTM)2.23B
Net Income(TTM)732.00K
Industry RankSector Rank
PM (TTM) 0.03%
ROA 0.02%
ROE 0.03%
Debt/Equity 0.6
Chartmill High Growth Momentum
EPS Q2Q%-9.48%
Sales Q2Q%-13.78%
EPS 1Y (TTM)24.76%
Revenue 1Y (TTM)-6.33%

ICUI Ownership

Ownership
Inst Owners116.08%
Shares24.69M
Float23.84M
Ins Owners0.96%
Short Float %4.7%
Short Ratio4.08

About ICUI

Company Profile

ICUI logo image ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 13,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.

Company Info

IPO: 1992-03-31

ICU MEDICAL INC

951 Calle Amanecer

San Clemente CALIFORNIA 92763 US

CEO: Vivek Jain

Employees: 13000

ICUI Company Website

ICUI Investor Relations

Phone: 19493662183

ICU MEDICAL INC / ICUI FAQ

What does ICU MEDICAL INC do?

ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 13,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.


Can you provide the latest stock price for ICU MEDICAL INC?

The current stock price of ICUI is 129.4 USD. The price decreased by -0.41% in the last trading session.


Does ICUI stock pay dividends?

ICUI does not pay a dividend.


How is the ChartMill rating for ICU MEDICAL INC?

ICUI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What do analysts say about ICU MEDICAL INC (ICUI) stock?

12 analysts have analysed ICUI and the average price target is 187.27 USD. This implies a price increase of 44.72% is expected in the next year compared to the current price of 129.4.


Is ICU MEDICAL INC (ICUI) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ICUI.


What is the expected growth for ICUI stock?

The Revenue of ICU MEDICAL INC (ICUI) is expected to decline by -1.33% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.